Positron Emission Tomograph(PET) Imaging Explores the Role of SF-DEVD-2 in Monitoring Tumor Efficacy

• Status: Recruiting
• Trial end date: 2024-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single arm study to determining the value of apoptotic molecular probe SF-DEVD-2 in the early evaluation of tumor efficacy and comparing it head-to-head wihe 18F-FDG(18F-2-fluoro-2-deoxy-D-glucose)

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Affiliated Hospital of Jiangnan University

Criteria

Inclusion Criteria:

1. Patients voluntarily signed informed consent;

2. Age18-70, male or female;

3. Diagnosed with stage 2 or 3 breast cancer

4. Solid tumors、masses larger than 2cm with lymph node metastasis

5. Pathology is HER3+、triple negative patients

6. Patients to be treated with neoadjuvant chemotherapy

Exclusion Criteria:

1. Age greater than or equal to 70 years old

2. Abnormal liver and kidney function (more than five times the normal value)

3. Diagnosis level of breast cancer stage 4 or second time tumor patients